Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer

Molecular Oncology

Volumn 8, Issue 1, 2014, Pages 20-26

  Montemurro, Filippo ^a   Prat, Aleix ^b   Rossi, Valentina ^a   Valabrega, Giorgio ^a   Sperinde, Jeff ^c   Peraldo Neia, Caterina ^a   Donadio, Michela ^d   Galván, Patricia ^b   Sapino, Anna ^e   Aglietta, Massimo ^a   Baselga, José ^f   Scaltriti, Maurizio ^f  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^c MONOGRAM BIOSCIENCES   (United States)

^d CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy free; HER2 enriched; Lapatinib; Microarray; Signature; Trastuzumab

Indexed keywords

CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GROWTH FACTOR RECEPTOR BOUND PROTEIN 7; LAPATINIB; NAVELBINE; PACLITAXEL; PROTEIN MDM2; TRASTUZUMAB;

ADULT; AGED; AMPLICON; ARTICLE; BREAST METASTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; GENE EXPRESSION; HUMAN; MIDDLE AGED; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PREDICTOR VARIABLE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GENE; TUMOR REGRESSION;

(H2T); (P95); CHEMOTHERAPY; CHEMOTHERAPY-FREE; COMPLETE REMISSION; CR; CT; HER2-ENRICHED; LAPATINIB; MICROARRAY; MINIMAL RESPONSE; MR; OS; OVERALL SURVIVAL; P95HER2; PARTIAL REMISSION; PD; PERSISTENCE ON PROTOCOL; PFS; PP; PR; PROGRESSION-FREE SURVIVAL; PROGRESSIVE DISEASE; RISK OF RELAPSE; ROR; SD; SIGNATURE; STABLE DISEASE; TOTAL HER2; TRASTUZUMAB;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; QUINAZOLINES; RECEPTOR, ERBB-2; TRANSCRIPTOME; TREATMENT OUTCOME;

EID: 84892965940     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.08.013     Document Type: Article

References (32)

1. Baselga J., Cortes J., Kim S.B., et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 2012, 366:109-119.
2. Baselga J., Bradbury I., Eidtmann H., et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012, 379:633-640.
3. Blackwell K.L., Burstein H.J., Storniolo A.M., et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J. Clin. Oncol. 2012, 30:2585-2592.
4. Carey L.A., Berry D., Ollila D., et al. Clinical and translational results of CALGB 40601: a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer. J. Clin. Oncol. 2013, 31:500. Meeting Abstracts.
5. Cortes J., Baselga J., Petrella T., et al. Pertuzumab monotherapy following trastuzumab-based treatment: activity and tolerability in patients with advanced HER2- positive breast cancer. J. Clin. Oncol. 2009, 27:1022. Meeting Abstracts.
6. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 2006, 355:2733-2743.
7. Gianni L., Pienkowski T., Im Y.H., et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012, 13:25-32.
8. Gomez H.L., Doval D.C., Chavez M.A., et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J. Clin. Oncol. 2008, 26:2999-3005.
9. Hamberg P., Bos M.M., Braun H.J., et al. Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial. Clin. Breast Cancer 2011, 11:103-113.
10. Huang W., Reinholz M., Weidler J., et al. Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay. Am. J. Clin. Pathol. 2010, 134:303-311.
11. Inoue K., Nakagami K., Mizutani M., et al. Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 trial group. Breast Cancer Res. Treat. 2010, 119:127-136.
12. Marty M., Cognetti F., Maraninchi D., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J. Clin. Oncol. 2005, 23:4265-4274.
13. Montemurro F., Rossi V., Rocca M.C., et al. Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. Cancer 2012, 118:17-26.
14. Nielsen T.O., Parker J.S., Leung S., et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin. Cancer Res. 2010, 16:5222-5232.
15. Parker J.S., Mullins M., Cheang M.C., et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 2009, 27:1160-1167.
16. Pegram M.D., Konecny G.E., O'Callaghan C., et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J. Natl. Cancer Inst. 2004, 96:739-749.
17. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
18. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 2005, 353:1659-1672.
19. Prat A., Baselga J. Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: one more step toward chemotherapy-free therapy. J. Clin. Oncol. 2013, 31:1703-1706.
20. Prat A., Parker J.S., Karginova O., et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010, 12:R68.
21. Prat A., Cheang M.C., Martin M., et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal a breast cancer. J. Clin. Oncol. 2013, 31:203-209.
22. Rimawi M.F., Mayer I.A., Forero A., et al. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J. Clin. Oncol. 2013.
23. Rimawi M.F., Mayer I.A., Forero A., et al. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J. Clin. Oncol. 2013, 31:1726-1731.
24. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005, 353:1673-1684.
25. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
26. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344:783-792.
27. Sperinde J., Jin X., Banerjee J., et al. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients. Clin. Cancer Res. 2010, 16:4226-4235.
28. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000, 92:205-216.
29. Vaz-Luis I., Winer E.P., Lin N.U. Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypesα. Ann. Oncol. 2013, 24:283-291.
30. Verma S., Miles D., Gianni L., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 2012, 367:1783-1791.
31. Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20:719-726.
32. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001, 2:127-137.